沙库巴曲缬沙坦防治肿瘤治疗相关心功能不全的效果分析

林艺婷; 韩晴; 郭小博; 张红梅

doi:10.12354/j.issn.1000-8179.2024.20240149

沙库巴曲缬沙坦防治肿瘤治疗相关心功能不全的效果分析

Efficacy analysis of sacubitril/valsartan in the prevention and treatment of cardiac dysfunction related to tumor therapy

摘要

摘要:
目的探讨沙库巴曲缬沙坦治疗肿瘤治疗相关心功能不全（cancer therapy-related cardiac dysfunction，CTRCD）的疗效。
方法汇总分析自建库至2023年3月发表于Pubmed、Web of Science、Cochrane Library、Medline、Embase五大数据库的沙库巴曲缬沙坦治疗CTRCD的所有文献，归纳总结用药时机、剂量、药物疗效等；梳理总结其预防CTRCD的临床研究。
结果使用沙库巴曲缬沙坦治疗CTRCD 3～12个月后，肿瘤患者NYHA心功能从Ⅱ～Ⅳ级改善为Ⅰ～Ⅱ级，LVEF上升幅度为3.0%～37.0%，NT-proBNP下降幅度为280.0～65 498.0 pg/mL。
结论沙库巴曲缬沙坦治疗CTRCD有效，在改善患者LVEF、GLS等指标方面具有较好的临床应用价值，使肿瘤患者抗肿瘤治疗得以继续、生存期得以延长。

Abstract:
Objective To investigate the efficacy of sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction (CTRCD).
Methods A comprehensive analysis of all the literature on sacubitril/valsartan therapy for CTRCD published in Pubmed, Web of Science, Cochrane Library, Medline, and Embase from the inception of the database up to March 2023 was conducted, summarizing the timing of drug administration, dosage, and efficacy, and further systematically summarizing the clinical studies on the use of the drug for the prevention of CTRCD.
Results After 3-12 months of treatment with sacubitril/valsartan for CTRCD, NYHA in cancer patients improved from grade Ⅱ-Ⅳ to grade Ⅰ-Ⅱ, LVEF increased by 3.0% to 37.0%, and NT-proBNP decreased by 280.0-65 498.0 pg/mL.
Conclusions The sacubitril/valsartan demonstrates efficacy in managing CTRCD and holds significant clinical utility in enhancing LVEF, GLS, and other patient indicators, thereby enabling the continuation of anti-tumor therapy and prolonging survival for cancer patients.

HTML全文

参考文献(24)

施引文献

资源附件(0)